Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence

Table 4 Comparison of clinicopathologic features

Variable	PLT			APGA			PAPAS
	< 148 × 109/L	≥148 × 109/L	P value	< 26.9	≥26.9	P value	< 2.41	≥2.41	P value
	(n = 111)	(n = 61)		(n = 105)	(n = 51)		(n = 43)	(n = 113)
HBV, yes/no	82/29	39/22	0.172	75/30	38/13	0.686	32/11	81/32	0.732
Sex, male/female	90/21	49/12	0.904	85/20	42/9	0.833	36/7	91/22	0.647
Median age in year	52.6	55.2	0.115	54	52.1	0.263	NA	NA	NA
Ascites, yes/no	8/103	9/52	0.113	12/93	4/47	0.489	5/38	11/102	0.958
Cirrhosis, yes/no	43/68	16/45	0.098	33/72	21/30	0.230	15/28	39/74	0.965
Tumor size, ≥ 5/< 5 cm	55/56	39/22	0.070	51/54	38/13	0.002	14/29	75/38	< 0.001
Tumor type, multiple/single	19/92	13/48	0.499	19/84	11/40	0.606	4/39	26/87	0.052
Vascular invasion, yes/no	11/100	3/58	0.252	7/98	6/45	0.440	2/41	11/102	0.482
Recurrence, yes/no	43/68	33/28	0.052	39/66	31/20	0.005	10/33	60/53	0.001
Median survival in mo	37.5	29.5	0.050	37.3	27.9	0.026	43.4	30.8	0.006

APGA: Aspartate aminotransferase/platelet count/γ-glutamyl transpeptidase/alpha-fetoprotein index; HBV: Hepatitis B virus; NA: Not applicable; PAPAS: Platelet count/age/alkaline phosphatase/alpha-fetoprotein/aspartate aminotransferase index; PLT: Platelet count.